<DOC>
	<DOC>NCT02567994</DOC>
	<brief_summary>After a screening, a 2-week, single-blind placebo run-in, 200 patients will be randomized in a 1 : 1 ratio to the addition of either once-daily Teneligliptin 20mg or sitagliptin 100mg to ongoing stable doses of glimepiride in combination with metformin for 24 weeks.</brief_summary>
	<brief_title>Tenelia Triple Combination Study</brief_title>
	<detailed_description>Subjects will visit the centers on Week 4, 12 and 24 during the entire 24-week treatment period. Total study duration will be approximately 28weeks and the subjects will be to practice exercise/diet control together.</detailed_description>
	<mesh_term>Diabetes Mellitus</mesh_term>
	<mesh_term>Diabetes Mellitus, Type 2</mesh_term>
	<mesh_term>Sitagliptin Phosphate</mesh_term>
	<criteria>1. Patients with Type 2 Diabetes Mellitus 2. Adults aged â‰¥ 19 years old 3. Patients with HbA1c 7%~11% at Screening and Runin visit</criteria>
	<gender>All</gender>
	<minimum_age>19 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>May 2016</verification_date>
</DOC>